Mepolizumab versus benralizumab for eosinophilic granulomatosis with polyangiitis (EGPA): A European real-life retrospective comparative study
(2025) In Journal of Autoimmunity 153.- Abstract
- Background: Following the results of the MANDARA trial, this real-life study aimed at comparing the effectiveness and safety profile of mepolizumab versus benralizumab in a European EGPA cohort. Methods: We conducted a retrospective observational comparative study including EGPA patients, who received mepolizumab or benralizumab at the asthma dose. Patients were matched 1:1 by sex, age, BVAS and oral corticosteroid (OCS) dosage at the treatment initiation (T0). Complete response (CR) and partial response (PR), disease activity, OCS, pulmonary parameters, eosinophil count, relapses, and safety outcomes were also compared at 3, 6 and 12 months. Results: Patients treated with mepolizumab or benralizumab (n = 88 each) were matched: 57 % were... (More)
- Background: Following the results of the MANDARA trial, this real-life study aimed at comparing the effectiveness and safety profile of mepolizumab versus benralizumab in a European EGPA cohort. Methods: We conducted a retrospective observational comparative study including EGPA patients, who received mepolizumab or benralizumab at the asthma dose. Patients were matched 1:1 by sex, age, BVAS and oral corticosteroid (OCS) dosage at the treatment initiation (T0). Complete response (CR) and partial response (PR), disease activity, OCS, pulmonary parameters, eosinophil count, relapses, and safety outcomes were also compared at 3, 6 and 12 months. Results: Patients treated with mepolizumab or benralizumab (n = 88 each) were matched: 57 % were females, median age was 54 years (IQR 45–60), median OCS dose 10 (7.5–12.5) and 10 (7–13) mg/day, median BVAS 4 (2–7) and 3 (2–8), respectively. 45.4 % of patients in the mepolizumab group and 51.1 % in the benralizumab group achieved CR or PR at T3, with CR steadily increasing during follow-up for both treatments. At T12, a higher CR rate was found in the benralizumab group (48.1 % vs 32.4 %, p = 0.005). No differences in BVAS, OCS, and respiratory parameters were observed between groups at the different timepoints. Throughout the follow-up, both treatments reduced eosinophil count, although a deeper reduction was found in the benralizumab group at all timepoints (p < 0.0001). Safety profile was comparable between patient groups. Conclusion: Mepolizumab and benralizumab showed comparable overall effectiveness and safety in EGPA. However, benralizumab achieved a higher CR rate at T12, and a deeper peripheral eosinophil reduction. © 2025 The Author(s) (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/a2f9b3eb-c3a1-42ac-ae8b-4753a9d53654
- author
- Mattioli, I. ; Mohammad, A.J. LU and Emmi, G.
- author collaboration
- organization
- publishing date
- 2025
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- ANCA-associated vasculitis, Benralizumab, Biologicals, Eosinophilic granulomatosis with polyangiitis (EGPA), Epidemiology, Interleukin-5, Mepolizumab, azathioprine, benralizumab, corticosteroid, cyclosporine, immunoglobulin, mepolizumab, methotrexate, mycophenolic acid, prednisone, rituximab, adult, arthralgia, Article, asthma, Churg Strauss syndrome, clinical feature, clinical outcome, cohort analysis, controlled study, disease activity, disease duration, drug efficacy, drug safety, drug withdrawal, eosinophil count, Europe, faintness, female, fever, first trimester pregnancy, follow up, forced expiratory volume, fracture, headache, herpes zoster, hospitalization, human, injection site erythema, injection site reaction, lower respiratory tract infection, lung function, lung infection, major clinical study, malaise, male, middle aged, myalgia, observational study, pregnancy, prevalence, rash, relapse, respiratory syncytial virus infection, retrospective study, second trimester pregnancy, sinusitis, systemic therapy, treatment response, urticaria
- in
- Journal of Autoimmunity
- volume
- 153
- article number
- 103398
- publisher
- Academic Press
- external identifiers
-
- scopus:105000853847
- pmid:40147217
- ISSN
- 0896-8411
- DOI
- 10.1016/j.jaut.2025.103398
- language
- English
- LU publication?
- yes
- id
- a2f9b3eb-c3a1-42ac-ae8b-4753a9d53654
- date added to LUP
- 2026-03-04 13:44:08
- date last changed
- 2026-03-05 03:00:08
@article{a2f9b3eb-c3a1-42ac-ae8b-4753a9d53654,
abstract = {{Background: Following the results of the MANDARA trial, this real-life study aimed at comparing the effectiveness and safety profile of mepolizumab versus benralizumab in a European EGPA cohort. Methods: We conducted a retrospective observational comparative study including EGPA patients, who received mepolizumab or benralizumab at the asthma dose. Patients were matched 1:1 by sex, age, BVAS and oral corticosteroid (OCS) dosage at the treatment initiation (T0). Complete response (CR) and partial response (PR), disease activity, OCS, pulmonary parameters, eosinophil count, relapses, and safety outcomes were also compared at 3, 6 and 12 months. Results: Patients treated with mepolizumab or benralizumab (n = 88 each) were matched: 57 % were females, median age was 54 years (IQR 45–60), median OCS dose 10 (7.5–12.5) and 10 (7–13) mg/day, median BVAS 4 (2–7) and 3 (2–8), respectively. 45.4 % of patients in the mepolizumab group and 51.1 % in the benralizumab group achieved CR or PR at T3, with CR steadily increasing during follow-up for both treatments. At T12, a higher CR rate was found in the benralizumab group (48.1 % vs 32.4 %, p = 0.005). No differences in BVAS, OCS, and respiratory parameters were observed between groups at the different timepoints. Throughout the follow-up, both treatments reduced eosinophil count, although a deeper reduction was found in the benralizumab group at all timepoints (p < 0.0001). Safety profile was comparable between patient groups. Conclusion: Mepolizumab and benralizumab showed comparable overall effectiveness and safety in EGPA. However, benralizumab achieved a higher CR rate at T12, and a deeper peripheral eosinophil reduction. © 2025 The Author(s)}},
author = {{Mattioli, I. and Mohammad, A.J. and Emmi, G.}},
issn = {{0896-8411}},
keywords = {{ANCA-associated vasculitis; Benralizumab; Biologicals; Eosinophilic granulomatosis with polyangiitis (EGPA); Epidemiology; Interleukin-5; Mepolizumab; azathioprine; benralizumab; corticosteroid; cyclosporine; immunoglobulin; mepolizumab; methotrexate; mycophenolic acid; prednisone; rituximab; adult; arthralgia; Article; asthma; Churg Strauss syndrome; clinical feature; clinical outcome; cohort analysis; controlled study; disease activity; disease duration; drug efficacy; drug safety; drug withdrawal; eosinophil count; Europe; faintness; female; fever; first trimester pregnancy; follow up; forced expiratory volume; fracture; headache; herpes zoster; hospitalization; human; injection site erythema; injection site reaction; lower respiratory tract infection; lung function; lung infection; major clinical study; malaise; male; middle aged; myalgia; observational study; pregnancy; prevalence; rash; relapse; respiratory syncytial virus infection; retrospective study; second trimester pregnancy; sinusitis; systemic therapy; treatment response; urticaria}},
language = {{eng}},
publisher = {{Academic Press}},
series = {{Journal of Autoimmunity}},
title = {{Mepolizumab versus benralizumab for eosinophilic granulomatosis with polyangiitis (EGPA): A European real-life retrospective comparative study}},
url = {{http://dx.doi.org/10.1016/j.jaut.2025.103398}},
doi = {{10.1016/j.jaut.2025.103398}},
volume = {{153}},
year = {{2025}},
}